TY-JUR T1 - MultiDrug /广泛耐药结核治疗结果在拉脱维亚，2000-2004 JF - 欧洲呼吸杂志Jo - Eur Respir J SP - 584 LP - 593 Do - 10.1183 / 09031936.00003710 VL - 36是 - 3 Au -Leimane, V. AU - Dravniece, G. AU - Riekstina, V. AU - Sture, I. AU - Kammerer, S. AU - Chen, M.P. AU - Skenders, G. AU - Holtz, T.H. Y1 - 2010/09/01 UR - //www.qdcxjkg.com/content/36/3/584.abstract N2 - In the present study, we characterised drug-resistance patterns, compared treatment outcome between extensively and nonextensively drug-resistant tuberculosis (non-XDR-TB) cases, and assessed risk factors for poor outcome in a high-prevalence country that screens all TB patients for first-line anti-TB drug resistance. We reviewed drug susceptibility test results among all pulmonary TB cases in Latvia diagnosed from 2000–2004, as well as demographic and clinical characteristics, drug-resistance patterns, and treatment outcomes. During the 5-yr period, 1,027 multidrug-resistant tuberculosis (MDR-TB) cases initiated treatment. Among all cases, the proportion that experienced an outcome of cure or completion increased from 66.2 to 70.2% (p = 0.06 for linear trend). Among the 48 (4.7%) XDR-TB cases, 18 (38%) were cured, four (8%) died, three (6%) defaulted, and treatment failed in 23 (48%). In proportional-hazards analysis, characteristics significantly associated with poor outcome included XDR-TB, being retired, presence of bilateral cavitation, and previous MDR-TB treatment history for those aged ≥55 yrs. Overall, treatment success among all MDR-TB cases increased over time. Strategies to prevent transmission of XDR-TB and to further improve treatment outcome are crucial for the future of TB control in Latvia. ER -